Cargando…
Intracerebroventricular gene therapy that delays neurological disease progression is associated with selective preservation of retinal ganglion cells in a canine model of CLN2 disease
CLN2 disease is one of a group of lysosomal storage disorders called the neuronal ceroid lipofuscinoses (NCLs). The disease results from mutations in the TPP1 gene that cause an insufficiency or complete lack of the soluble lysosomal enzyme tripeptidyl peptidase-1 (TPP1). TPP1 is involved in lysosom...
Autores principales: | Whiting, Rebecca E.H., Jensen, Cheryl A., Pearce, Jacqueline W., Gillespie, Lauren E., Bristow, Daniel E., Katz, Martin L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957944/ https://www.ncbi.nlm.nih.gov/pubmed/27039708 http://dx.doi.org/10.1016/j.exer.2016.03.023 |
Ejemplares similares
-
Extraneuronal pathology in a canine model of CLN2 neuronal ceroid lipofuscinosis after intracerebroventricular gene therapy that delays neurological disease progression
por: Katz, M L, et al.
Publicado: (2017) -
Characterization of neurological disease progression in a canine model of CLN5 neuronal ceroid lipofuscinosis
por: Meiman, Elizabeth J., et al.
Publicado: (2022) -
Long-term safety and dose escalation of intracerebroventricular CLN5 gene therapy in sheep supports clinical translation for CLN5 Batten disease
por: Mitchell, Nadia L., et al.
Publicado: (2023) -
Efficacy of dual intracerebroventricular and intravitreal CLN5 gene therapy in sheep prompts the first clinical trial to treat CLN5 Batten disease
por: Murray, Samantha J., et al.
Publicado: (2023) -
Dose selection for intracerebroventricular cerliponase alfa in children with CLN2 disease, translation from animal to human in a rare genetic disease
por: Hammon, Kevin, et al.
Publicado: (2021)